Advertisement

Neurotherapeutics

, Volume 7, Issue 1, pp 31–42 | Cite as

Calpain as a therapeutic target in traumatic brain injury

  • Kathryn E. SaatmanEmail author
  • Jennifer Creed
  • Ramesh Raghupathi
Review Article

Summary

The family of calcium-activated neutral proteases, calpains, appears to play a key role in neuropathologic events following traumatic brain injury (TBI). Neuronal calpain activation has been observed within minutes to hours after either contusive or diffuse brain trauma in animals, suggesting that calpains are an early mediator of neuronal damage. Whereas transient calpain activation triggers numerous cell signaling and remodeling events involved in normal physiological processes, the sustained calpain activation produced by trauma is associated with neuron death and axonal degeneration in multiple models of TBI. Nonetheless, the causal relationship between calpain activation and neuronal death is not fully understood. Much remains to be learned regarding the endogenous regulatory mechanisms for controlling calpain activity, the roles of different calpain isoforms, and the in vivo substrates affected by calpain. Detection of stable proteolytic fragments of the submembrane cytoskeletal protein αII-spectrin specific for cleavage by calpains has been the most widely used marker of calpain activation in models of TBI. More recently, these protein fragments have been detected in the cerebrospinal fluid after TBI, driving interest in their potential utility as TBI-associated biomarkers. Post-traumatic inhibition of calpains, either direct or indirect through targets related to intracellular calcium regulation, is associated with attenuation of functional and behavioral deficits, axonal pathology, and cell death in animal models of TBI. This review focuses on the current state of knowledge of the role of calpains in TBI-induced neuropathology and effectiveness of calpain as a therapeutic target in the acute post-traumatic period.

Key Words

Biomarker calcium neuroprotection protease proteolysis spectrin 

References

  1. 1.
    Bevers MB, Neumar RW. Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab 2008;28: 655–673.PubMedCrossRefGoogle Scholar
  2. 2.
    Hosfield CM, Elce JS, Davies PL, Jia Z. Crystal structure of calpain reveals the structural basis for Ca2+-dependent protease activity and a novel mode of enzyme activation. EMBO J 1999;18: 6880–6889.PubMedCrossRefGoogle Scholar
  3. 3.
    Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83: 731–801.PubMedGoogle Scholar
  4. 4.
    Wu HY, Lynch DR. Calpain and synaptic function. Mol Neurobiol 2006;33: 215–236.PubMedCrossRefGoogle Scholar
  5. 5.
    Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 2008;38: 78–100.PubMedCrossRefGoogle Scholar
  6. 6.
    Kampfl A, Posmantur R, Nixon R, et al. mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem 1996;67: 1575–1583.PubMedCrossRefGoogle Scholar
  7. 7.
    Saatman KE, Bozyczko-Coyne D, Marcy V, Siman R, McIntosh TK. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 1996;55: 850–860.PubMedCrossRefGoogle Scholar
  8. 8.
    Arai A, Vanderklish P, Kessler M, Lee K, Lynch G. A brief period of hypoxia causes proteolysis of cytoskeletal proteins in hippocampal slices. Brain Res 1991;555: 276–280.PubMedCrossRefGoogle Scholar
  9. 9.
    Hiramatsu K, Kassell NF, Lee KS. Improved posthypoxic recovery of synaptic transmission in gerbil neocortical slices treated with a calpain inhibitor. Stroke 1993;24: 1725–1728.PubMedGoogle Scholar
  10. 10.
    Ray SK, Hogan EL, Banik NL. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Brain Res Rev 2003;42: 169–185.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhao X, Posmantur R, Kampfl A, et al. Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. J Cereb Blood Flow Metab 1998;18: 161–167.PubMedCrossRefGoogle Scholar
  12. 12.
    Saatman KE, Abai B, Grosvenor A, Vorwerk CK, Smith DH, Meaney DF. Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice. J Cereb Blood Flow Metab 2003;23: 34–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma 2005;22: 252–265.PubMedCrossRefGoogle Scholar
  14. 14.
    Kupina NC, Nath R, Bemath EE, et al. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma 2001;18: 1229–1240.PubMedCrossRefGoogle Scholar
  15. 15.
    Biiki A, Siman R, Trojanowski JQ, Povlishock JT. The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol Exp Neurol 1999;58: 365–375.CrossRefGoogle Scholar
  16. 16.
    McGinn MJ, Kelley BJ, Akinyi L, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol 2009;68: 241–249.PubMedCrossRefGoogle Scholar
  17. 17.
    Huh JW, Franklin MA, Widing AG, Raghupathi R. Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. Dev Neurosci 2006;28: 466–476.PubMedCrossRefGoogle Scholar
  18. 18.
    Kupina NC, Detloff MR, Bobrowski WF, Snyder BJ, Hall ED. Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury. Exp Neurol 2003;180: 55–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Pike BR, Zhao X, Newcomb JK, et al. Regional calpain and caspase-3 proteolysis of α-spectrin after traumatic brain injury. Neuroreport 1998;9: 2437–2442.PubMedCrossRefGoogle Scholar
  20. 20.
    Deng Y, Thompson BM, Gao X, Hall ED. Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury. Exp Neurol 2007;205: 154–165.PubMedCrossRefGoogle Scholar
  21. 21.
    Thompson SN, Gibson TR, Thompson BM, Deng Y, Hall ED. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice. Exp Neurol 2006;201: 253–265.PubMedCrossRefGoogle Scholar
  22. 22.
    DeRidder MN, Simon MJ, Siman R, Auberson YP, Raghupathi R, Meaney DF. Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol Dis 2006;22: 165–176.PubMedCrossRefGoogle Scholar
  23. 23.
    Pike BR, Zhao X, Newcomb JK, Glenn CC, Anderson DK, Hayes RL. Stretch injury causes calpain and caspase-3 activation and necrotic and apoptotic cell death in septo-hippocampal cell cultures. J Neurotrauma 2000;17: 283–298.PubMedCrossRefGoogle Scholar
  24. 24.
    McCracken E, Hunter AJ, Patel S, Graham DI, Dewar D. Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head-injured patients. J Neurotrauma 1999;16: 749–761.PubMedCrossRefGoogle Scholar
  25. 25.
    Newcomb JK, Kampfl A, Posmantur RM, et al. Immunohistochemical study of calpain-mediated breakdown products to a-spectrin following controlled cortical impact injury in the rat. J Neurotrauma 1997;14: 369–383.PubMedCrossRefGoogle Scholar
  26. 26.
    Huh JW, Widing AG, Raghupathi R. Basic science; repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: a preliminary report. J Neurotrauma 2007;24: 15–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Maki M, Takano E, Mori H, et al. All four internally repetitive domains of pig calpastatin possess inhibitory activities against calpains I and II. FEBS Lett 1987;223: 174–180.PubMedCrossRefGoogle Scholar
  28. 28.
    Hood JL, Logan BB, Sinai AP, Brooks WH, Roszman TL. Association of the calpain/calpastatin network with subcellular organelles. Biochem Biophys Res Commun 2003;310: 1200–1212.PubMedCrossRefGoogle Scholar
  29. 29.
    Garcia M, Bondada V, Geddes JW. Mitochondrial localization of mu-calpain. Biochem Biophys Res Commun 2005;338: 1241–1247.PubMedCrossRefGoogle Scholar
  30. 30.
    Tremper-Wells B, Vallano ML. Nuclear calpain regulates Ca2+-dependent signaling via proteolysis of nuclear Ca2+/calmodulin-dependent protein kinase type IV in cultured neurons. J Biol Chem 2005;280: 2165–2175.PubMedCrossRefGoogle Scholar
  31. 31.
    Kilinc D, Gallo G, Barbee KA. Mechanical membrane injury induces axonal beading through localized activation of calpain. Exp Neurol 2009;219: 553–561.PubMedCrossRefGoogle Scholar
  32. 32.
    Tullio RD, Passalacqua M, Avema M, Salamino F, Melloni E, Pontremoli S. Changes in intracellular localization of calpastatin during calpain activation. Biochem J 1999;343 Pt 2: 467–472.PubMedCrossRefGoogle Scholar
  33. 33.
    Newcomb JK, Pike BR, Zhao X, Banik NL, Hayes RL. Altered calpastatin protein levels following traumatic brain injury in rat. J Neurotrauma 1999;16: 1–11.PubMedCrossRefGoogle Scholar
  34. 34.
    De Tullio R, Avema M, Stifanese R, et al. Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons. Arch Biochem Biophys 2007;465: 148–156.PubMedCrossRefGoogle Scholar
  35. 35.
    Foozer H, Surles N, Kizhakke Madathil S, Saatman K. Behavioral dysfunction and histological damage in calpastatin knockout mice after controlled cortical impact injury. J Neurotrauma 2007;24: 1250 (abstract).Google Scholar
  36. 36.
    Ringger NC, Tolentino PJ, McKinsey DM, Pike BR, Wang KK, Hayes RL. Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats. J Neurotrauma 2004;21: 829–841.PubMedCrossRefGoogle Scholar
  37. 37.
    Guttmann RP, Elce JS, Bell PD, Isbell JC, Johnson GV. Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J Biol Chem 1997;272: 2005–2012.PubMedCrossRefGoogle Scholar
  38. 38.
    Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010;7: 51–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Roberts-Lewis JM, Savage MJ, Marcy VR, Pinsker LR, Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci 1994;14: 3934–3944.PubMedGoogle Scholar
  40. 40.
    Saido TC, Yokota M, Nagao S, et al. Spatial resolution of fodrin proteolysis in postischemic brain. J Biol Chem 1993;268: 25239–25243.PubMedGoogle Scholar
  41. 41.
    Wang KK. Calpain and caspase: can you tell the difference? [Erratum in: Trends Neurosci 2000;23:59] Trends Neurosci 2000;23: 20–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Taft WC, Yang K, Dixon CE, Hayes RL. Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. J Neurotrauma 1992;9: 281–290.PubMedCrossRefGoogle Scholar
  43. 43.
    Franz G, Beer R, Intemann D, et al. Temporal and spatial profile of Bid cleavage after experimental traumatic brain injury. J Cereb Blood Flow Metab 2002;22: 951–958.PubMedCrossRefGoogle Scholar
  44. 44.
    von Reyn CR, Spaethling JM, Mesfin MN, et al. Calpain mediates proteolysis of the voltage-gated sodium channel α-subunit. J Neurosci 2009;29: 10350–10356.CrossRefGoogle Scholar
  45. 45.
    Saatman KE, Graham DI, McIntosh TK. The neuronal cytoskeleton is at risk after mild and moderate brain injury. J Neurotrauma 1998;15: 1047–1058.PubMedCrossRefGoogle Scholar
  46. 46.
    Posmantur RM, Hayes RL, Dixon CE, Taft WC. Neurofilament 68 and Neurofilament 200 protein levels decrease after TBI. J Neurotrauma 1994; 11: 533–545.PubMedCrossRefGoogle Scholar
  47. 47.
    Serbest G, Burkhardt MF, Siman R, Raghupathi R, Saatman KE. Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice. Neurochem Res 2007;32: 2006–2014.PubMedCrossRefGoogle Scholar
  48. 48.
    Huh JW, Laurer HL, Raghupathi R, Helfaer MA, Saatman KE. Rapid loss and partial recovery of neurofilament immunostaining following focal brain injury in mice. Exp Neurol 2002;175: 198–208.PubMedCrossRefGoogle Scholar
  49. 49.
    Posmantur RM, Zhao X, Kampft A, Clifton GL, Hayes RL. Immunoblot analyses of the relative contributions of cysteine and aspartic proteases to neurofilament breakdown products following experimental brain injury in rats. Neurochem Res 1998;23: 1265–1276.PubMedCrossRefGoogle Scholar
  50. 50.
    Posmantur R, Kampft A, Siman R, Liu J, Zhao X, Clifton GL, Hayes RL. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997;77: 875–888.PubMedCrossRefGoogle Scholar
  51. 51.
    Liu MC, Akle V, Zheng W, et al. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem 2006;98: 700–712.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhang Z, Ottens AK, Sadasivan S, et al. Calpain-mediated collapsin response mediator protein-1, -2, and-4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma 2007;24: 460–472.PubMedCrossRefGoogle Scholar
  53. 53.
    Liu MC, Akle V, Zheng W, et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J 2006;394: 715–725.PubMedCrossRefGoogle Scholar
  54. 54.
    Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 2004;16: 311–320.PubMedCrossRefGoogle Scholar
  55. 55.
    Hicks R, Soares H, Smith D, McIntosh T. Temporal and spatial characteristics of neuronal injury following lateral fluid-percussion brain injury in the rat. Acta Neuropathol 1996;91: 236–246.PubMedCrossRefGoogle Scholar
  56. 56.
    Fineman I, Hovda DA, Smith M, Yoshino A, Becker DP. Concussive brain injury is associated with a prolonged accumulation of calcium: a 45Ca autoradiographic study. Brain Res 1993;624: 94–102.PubMedCrossRefGoogle Scholar
  57. 57.
    Hall ED, Gibson TR, Pavel KM. Lack of a gender difference in post-traumatic neurodegeneration in the mouse controlled cortical impact injury model. J Neurotrauma 2005;22: 669–679.PubMedCrossRefGoogle Scholar
  58. 58.
    Farkas O, Lifshitz J, Povlishock JT. Mechanoporation induced by diffuse traumatic brain injury: an irreversible or reversible response to injury? J Neurosci 2006;26: 3130–3140.PubMedCrossRefGoogle Scholar
  59. 59.
    Hicks RR, Smith DH, Lowenstein DH, Saint Marie R, McIntosh TK. Mild experimental brain injury in the rat induces cognitive deficits associated with regional neuronal loss in the hippocampus. J Neurotrauma 1993;10: 405–414.PubMedCrossRefGoogle Scholar
  60. 60.
    Beer R, Franz G, Srinivasan A, et al. Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem 2000;75: 1264–1273.PubMedCrossRefGoogle Scholar
  61. 61.
    Clark RSB, Kochanek PM, Watkins SC, et al. Caspase-3 mediated neuronal death after traumatic brain injury in rats. J Neurochem 2000;74: 740–753.PubMedCrossRefGoogle Scholar
  62. 62.
    Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci 1997;17: 7415–7424.PubMedGoogle Scholar
  63. 63.
    Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 2004;14: 215–222.PubMedCrossRefGoogle Scholar
  64. 64.
    Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT; Workshop Scientific Team and Advisory Panel Members. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008;25: 719–738.PubMedCrossRefGoogle Scholar
  65. 65.
    Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol 2004;14: 202–209.PubMedCrossRefGoogle Scholar
  66. 66.
    Ottens AK, Golden EC, Bustamante L, Hayes RL, Denslow ND, Wang KK. Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. J Neurochem 2008;104: 1404–1414.PubMedCrossRefGoogle Scholar
  67. 67.
    Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid α II-spectrin and calpain-cleaved α II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 2001;78: 1297–1306.PubMedCrossRefGoogle Scholar
  68. 68.
    Aikman J, O’Steen B, Silver X, et al. α-II-spectrin after controlled cortical impact in the immature rat brain. Dev Neurosci 2006;28: 457–465.PubMedCrossRefGoogle Scholar
  69. 69.
    Ringger NC, O’Steen BE, Brabham JG, et al. A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J Neurotrauma 2004;21: 1443–1456.PubMedCrossRefGoogle Scholar
  70. 70.
    Farkas O, Polgár B, Szekeres-Barthó J, Dóczi T, Povlishock JT, Büki A. Spectrin breakdown products in the cerebrospinal fluid in severe head injury: preliminary observations. Acta Neurochir (Wien) 2005;147: 855–861.CrossRefGoogle Scholar
  71. 71.
    Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of all-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 2007;24: 354–366.PubMedCrossRefGoogle Scholar
  72. 72.
    Cardali S, Maugeri R. Detection of all-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci 2006;50: 25–31.PubMedGoogle Scholar
  73. 73.
    Brophy GM, Pineda JA, Papa L, et al. αII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma 2009;26: 471–479.PubMedCrossRefGoogle Scholar
  74. 74.
    Cox CD, West EJ, Liu MC, Wang KK, Hayes RL, Lyeth BG. Dicyclomine, an Ml muscarinic antagonist, reduces biomarker levels, but not neuronal degeneration, in fluid percussion brain injury. J Neurotrauma 2008;25: 1355–1365.PubMedCrossRefGoogle Scholar
  75. 75.
    Haranishi Y, Kawata R, Fukuda S, et al. Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. Eur J Anaesthesiol 2005;22: 140–147.PubMedCrossRefGoogle Scholar
  76. 76.
    Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A 1996;93: 3428–3433.PubMedCrossRefGoogle Scholar
  77. 77.
    Saatman KE, Zhang C, Bartus RT, Mclntosh TK. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. J Cereb Blood Flow Metab 2000;20: 66–73.PubMedCrossRefGoogle Scholar
  78. 78.
    Lubisch W, Beckenbach E, Bopp S, et al. Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem 2003;46: 2404–2412.PubMedCrossRefGoogle Scholar
  79. 79.
    Markgraf CG, Velayo NL, Johnson MP, et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998;29: 152–158.PubMedGoogle Scholar
  80. 80.
    Buki A, Farkas O, Doczi T, Povlishock JT. Reinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury. J Neurotrauma 2003;20: 261–268.PubMedCrossRefGoogle Scholar
  81. 81.
    Ai J, Liu E, Wang J, Chen Y, Yu J, Baker AJ. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma 2007;24: 960–978.PubMedCrossRefGoogle Scholar
  82. 82.
    Guttmann RP, Baker DL, Seifert KM, Cohen AS, Coulter DA, Lynch DR. Specific proteolysis of the NR2 subunit at multiple sites by calpain. J Neurochem 2001;78: 1083–1093.PubMedCrossRefGoogle Scholar
  83. 83.
    Saatman KE, Bareyre FM, Grady MS, Mclntosh TK. Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J Neuropathol Exp Neurol 2001;60: 183–194.PubMedGoogle Scholar
  84. 84.
    Liu L, Yenari MA. Therapeutic hypothermia: neuroprotective mechanisms. Front Biosci 2007;12: 816–825.PubMedCrossRefGoogle Scholar
  85. 85.
    Büki A, Koizumi H, Povlishock JT. Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp Neurol 1999;159: 319–328.PubMedCrossRefGoogle Scholar
  86. 86.
    Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol 2007;6: 29–38.PubMedCrossRefGoogle Scholar
  87. 87.
    Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001;344: 556–563.PubMedCrossRefGoogle Scholar
  88. 88.
    Pettus EH, Christman CW, Giebel ML, Povlishock JT. Traumatically induced altered membrane permeability: its relationship to traumatically induced reactive axonal change. J Neurotrauma 1994; 11: 507–522.PubMedCrossRefGoogle Scholar
  89. 89.
    Deng-Bryant Y, Singh IN, Carrico KM, Hall ED. Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J Cereb Blood Flow Metab 2008;28: 1114–1126.PubMedCrossRefGoogle Scholar
  90. 90.
    Okonkwo DO, Büki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 1999;10: 353–358.PubMedCrossRefGoogle Scholar
  91. 91.
    Büki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma 1999;16: 511–521.PubMedCrossRefGoogle Scholar
  92. 92.
    Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2009;29: 87–97.PubMedCrossRefGoogle Scholar
  93. 93.
    Kupina NC, Detloff MR, Dutta S, Hall ED. Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. J Cereb Blood Flow Metab 2002;22: 1212–1221.PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  • Kathryn E. Saatman
    • 1
    Email author
  • Jennifer Creed
    • 2
  • Ramesh Raghupathi
    • 2
  1. 1.Spinal Cord and Brain Injury Research Center, Department of PhysiologyUniversity of KentuckyLexington
  2. 2.Department of Neurobiology and AnatomyDrexel University College of MedicinePhiladelphiaPennsylvania

Personalised recommendations